Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung

por Holzer, Timothy R., Fulford, Angie D., Nedderman, Drew M., Umberger, Tara S., Hozak, Rebecca R., Joshi, Adarsh, Melemed, Symantha A., Benjamin, Laura E., Plowman, Gregory D., Schade, Andrew E., Ackermann, Bradley L., Konrad, Robert J., Nasir, Aejaz
Publicado 2013

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

por Tabernero, J, Hozak, R R, Yoshino, T, Cohn, A L, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, Ciuleanu, T -E, Portnoy, D C, Prausová, J, Muro, K, Siegel, R W, Konrad, R J, Ouyang, H, Melemed, S A, Ferry, D, Nasroulah, F, Van Cutsem, E
Publicado 2018

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

por Fuchs, Charles S, Tabernero, Josep, Tomášek, Jiří, Chau, Ian, Melichar, Bohuslav, Safran, Howard, Tehfe, Mustapha A, Filip, Dumitru, Topuzov, Eldar, Schlittler, Luis, Udrea, Anghel Adrian, Campbell, William, Brincat, Stephen, Emig, Michael, Melemed, Symantha A, Hozak, Rebecca R, Ferry, David, Caldwell, C William, Ajani, Jaffer A
Publicado 2016

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed...

por Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
Publicado 2015